Today: 20 March 2026
Subscribe
Browse Category

NYSE:NVO 30 December 2025 - 13 January 2026

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer shares fell 0.8% to $25.27 after CEO Albert Bourla compared the obesity drug cash-pay market to Viagra’s early days. The company, which acquired Metsera for up to $10 billion, aims to start up to 10 Phase 3 trials for Metsera’s GLP-1 drug by end-2026. Eli Lilly and Novo Nordisk shares rose, while Pfizer trails rivals in the obesity market.
13 January 2026
···
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk shares rose 3% in Copenhagen on Friday after Amazon Pharmacy began offering the Wegovy weight-loss pill with insurance and cash-pay options. U.S.-listed ADRs gained 2.6%. Amazon set insured prices as low as $25 per month, with cash prices starting at $149. Investors are watching CEO Mike Doustdar’s upcoming appearance at the J.P. Morgan Healthcare Conference.
11 January 2026
···
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill through insurance and cash-pay, with uninsured customers paying from $149 a month and some insured paying $25. The pill, approved by the FDA in December, will be added to Amazon’s kiosks and is also available at CVS, Costco, and via telehealth. Novo’s U.S. shares rose about 5% to $60.19 Friday morning. Analysts remain split on Novo’s 2026 outlook.
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon Pharmacy began offering Novo Nordisk’s Wegovy pill nationwide, with insured customers paying as little as $25 per month and uninsured starting at $149. The oral weight-loss drug, approved by U.S. regulators in December, is available for delivery in all 50 states. Amazon shares fell 0.7% to $244.58 in early trading. Broader markets were little changed.
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S. shares rose 1.4% in premarket trading after the company denied any relationship with SaveRxCanada.to, which claims to sell India-sourced Ozempic to U.S. patients at $280 per pen. Novo said it has not supplied Ozempic to the platform. The dispute comes as drug pricing faces renewed political scrutiny and ahead of the J.P. Morgan Healthcare Conference.
9 January 2026
···
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly shares fell 3.6% to $1,041.51 in after-hours trading Monday after Novo Nordisk launched a pill version of its Wegovy weight-loss drug in the U.S. Novo’s shares rose 5.2% as investors reacted to new pricing and distribution details. Lilly’s stock traded as low as $1,034 earlier in the session. Investors await commentary at the J.P. Morgan Healthcare Conference and Lilly’s earnings call.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
1 2 3 4 5 … 7

Stock Market Today

  • TXSE Poaches NYSE Texas Leader as Global Head of Listings
    March 20, 2026, 12:33 PM EDT. The Texas Stock Exchange (TXSE) secured Liz Hocker, the former regional head of capital markets at NYSE Texas, as its new global head of listings. Greg Ferrari, ex-head of North American exchange trading at Nasdaq, joined TXSE as chief operating officer. TXSE, set to launch later this year, previously recruited the Securities and Exchange Commission's former head of trading and markets. Hocker brings two decades of industry experience, including nearly five years managing new listings for the Southwest U.S. at Nasdaq. Ferrari's 15-plus years at Nasdaq involved leadership in transaction services and U.S. options. TXSE's hiring spree signals fierce competition among U.S. regional exchanges.
Go toTop